Form D · Pharmaceuticals
Branch Therapeutics, Inc.
Houston, TX · CIK 0002067625
Offering snapshot reported May 23, 2025 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 30, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 23, 2025 | Initial | $3,999,994 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-547059
Source: Form D, filed May 23, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sourav Banerjee | Director |
| Christopher Hulme | Director |
| Curtis Thorne | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2450 Holcombe Blvd Tmci Partners Office 1.319
Houston, TX, 77021
Phone: 615-351-1950
Houston, TX, 77021
Phone: 615-351-1950